Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
Status:
Unknown status
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Using transcriptomics and proteomics to gain insights in the development of psoriasiform skin
lesions under anti-tumor necrosis factor (TNF) therapy, and predicting response to
ustekinumab.